Novo Holdings Planetary Health Annual Review/Business Update

The Novo Holdings Planetary Health Investments team today published its 2024 review.

Highlights from 2024 include:

• Transitioned from Bioindustrial Investments to Planetary Health Investments, expanding focus beyond biosolutions

• Increased allocation target for the green transition to 10% by 2030 (alongside the Capital Investments team)

• Executed nine new deals, seven internal financing rounds and one exit

• Expanded geographic focus, including first investment in India with AgNext

• Established team presence in Singapore with two key hires

• Strengthened the Novo Advisory Group with two new members and significantly expanded team

• Read the full review here

The Planetary Health Investments strategy focuses on investing in systems that tackle the world’s most pressing environmental and social challenges, expanding beyond the historical focus on biosolutions to include a broader range of transformative technologies. This strategy directly supports the Novo Nordisk Foundation’s mission to advance the green transition of society.

Anders Spohr, Managing Partner and Head of Planetary Health Investments, said: “2024 has been a year of growth and evolution for our investment team, with our transition in June from Bioindustrial Investments to Planetary Health Investments. This underscores Novo Holdings’ belief that addressing the health and wellbeing of the planet requires us to go beyond biology-based solutions and include a broader range of technologies.”

Planetary Health Investments operates alongside Novo Holdings’ Seed, Growth, Asia, Venture and Principal Investments teams, enabling investment in life science companies at every stage of development.